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Background: Simultaneous isolation of nucleic acids and proteins from a single biological sample facilitates
meaningful data interpretation and reduces time, cost and sampling errors. This is particularly relevant for rare
human and animal specimens, often scarce, and/or irreplaceable. TRIzolW and TRIzolWLS are suitable for
simultaneous isolation of RNA, DNA and proteins from the same biological sample. These reagents are widely used
for RNA and/or DNA isolation, while reports on their use for protein extraction are limited, attributable to technical
difficulties in protein solubilisation.
Results: TRIzolWLS was used for RNA isolation from 284 human colon cancer samples, including normal colon
mucosa, tubulovillous adenomas, and colon carcinomas with proficient and deficient mismatch repair system.
TRIzolW was used for RNA isolation from human colon cancer cells, from brains of transgenic Alzheimer’s disease
mice model, and from cultured mouse cortical neurons. Following RNA extraction, the TRIzolW-chloroform fractions
from human colon cancer samples and from mouse hippocampus and frontal cortex were stored for 2 years and 3
months, respectively, at −80°C until used for protein isolation.
Simple modifications to the TRIzolW manufacturer’s protocol, including Urea:SDS solubilization and sonication,
allowed improved protein recovery yield compared to the TRIzolW manufacturer’s protocol. Following SDS-PAGE
and Ponceau and Coomassie staining, recovered proteins displayed wide molecular weight range and staining
pattern comparable to those obtainable with commonly used protein extraction protocols. We also show that
nuclear and cytosolic proteins can be easily extracted and detected by immunoblotting, and that posttranslational
modifications, such as protein phosphorylation, are detectable in proteins recovered from TRIzolW-chloroform
fractions stored for up to 2 years at −80°C.
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Conclusions: We provide a novel approach to improve protein recovery from samples processed for nucleic acid
extraction with TRIzolW and TRIzolWLS compared to the manufacturer`s protocol, allowing downstream
immunoblotting and evaluation of steady-state relative protein expression levels. The method was validated in large
sets of samples from multiple sources, including human colon cancer and brains of transgenic Alzheimer’s disease
mice model, stored in TRIzolW-chloroform for up to two years. Collectively, we provide a faster and cheaper
alternative to the TRIzolW manufacturer`s protein extraction protocol, illustrating the high relevance, and wide
applicability, of the present protein isolation method for the immunoblot evaluation of steady-state relative protein
expression levels in samples from multiple sources, and following prolonged storage.
Keywords: Protein extraction, Sonication, TRIzolW protein isolation, Long-term sample storage in TRIzolW, Ponceau S
as loading control in immunoblotingBackground
The understanding of the molecular events taking place
in cells and tissues under physiological or pathological
conditions is the major goal of molecular biology. With
this purpose, genome, transcriptome and proteome ana-
lysis are common procedures, made possible through
DNA, RNA and protein extraction and analysis. Cur-
rently, multiple protocols and reagents can be used for
DNA, RNA or protein extraction and isolation. However,
the development of reagents that allow the routine isola-
tion of DNA, RNA and proteins from a single sample,
such as TRIzolW, has contributed to maximizing the in-
formation that can be extracted from valuable research
samples.
TRIzolW and TRIzolWLS are ready-to-use commer-
cially available reagents, consisting of a monophasic so-
lution of phenol and guanidine isothiocyanate, allowing
the isolation of DNA, RNA and proteins from cell cul-
ture and tissue samples of multiple sources [1]. Numer-
ous publications report the use of TRIzolW for nucleic
acid isolation. In contrast, only few studies report the
utility of this reagent for protein isolation, mainly due to
technical difficulties in the solubilization of the isolated
protein fraction [2-4]. One of the major limitations in
research using human clinical and animal model samples
is the amount of material available, which is most often
scarce, allowing limited downstream applications. There-
fore, the collection of a proper amount of nucleic acids
and proteins for subsequent analysis becomes crucial. In
addition, the simultaneous isolation of DNA, RNA and
proteins from a single sample facilitates the meaningful
interpretation and correlation of genome, transcriptome
and proteome data, while reducing time, cost and sam-
pling error [3-5]. An additional advantage reported using
TRIzolW for protein isolation is related to the reduced
loss of protein, compared with previous sample prepar-
ation methods, by preventing protein aggregation during
salt clearance [6].
In the present study, we report the use of the
TRIzolWLS reagent for protein isolation from 284 humancolon cancer (CC) samples stored at −80°C for 2 years in
TRIzolW-chloroform, following RNA extraction. We also
report the use of TRIzolW reagent for protein isolation
from amyloid precursor protein (APP)/Presenilin 1 (PS1)
double-transgenic (APP/PS1) and wild-type mice hippo-
campus and cortex brain regions, as well as from mouse
primary cortical neurons. Previous studies have reported
the extraction of proteins from samples stored in
phenol-ethanol supernatants for up to 6 months at
−80°C [3], and up to 3 years at −20°C [2], by
implementing modifications to the TRIzolW manufac-
turer’s protocol, to overcome difficulties in protein solu-
bilisation. Interestingly, sample lysis by automated
frozen disruption (AFD) prior to RNA and protein ex-
traction using TRIzolW was shown to provide compar-
able RNA, and higher protein recovery yield, as
compared to direct sample homogeneization in TRIzolW,
and may be preferred in the case of coupled RNA and
protein analysis [4]. However, TRIzolW is widely used for
total RNA extraction, with sample disruption being
mostly performed directly in TRIzolW, with or without
mechanical sample disruption. Furthermore, in most
cases, the remainder fractions containing DNA and pro-
tein are very often discarded, thus limiting information
obtainable from these samples. In this study, we present
an alternative and simple modification to the TRIzolW
and TRIzolWLS manufacturer’s protocol, applicable to
samples processed directly in TRIzolW for nucleic acid
extraction. This resulted in a fast solubilisation of pro-
tein pellets. 1D SDS-PAGE gel separation provided pro-
tein patterns comparable to those obtained with other
commonly used methods for total protein extraction,
following Ponceau and Coomassie staining, although
with lower protein recovery. Importantly, our modified
protocol displayed superior recovery performance and
yield, compared to the TRIzolW manufacturer’s protocol,
and allowed the subsequent immunoblot detection and
relative evaluation of the steady-state levels of relevant
proteins in human cancer, and Alzheimer's disease (AD),
including post-translationally modified (phosphorylated),
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cannot attest the method would be suitable for quantita-
tive protein analysis. This highlights the relevance of the
present method and its utility for research efforts involv-
ing small amounts of sample material, from human can-
cer samples to mouse models of disease, and its
applicability to the immunoblot evaluation of steady-
state relative protein expression levels in samples from
multiple sources, following prolonged storage.
Methods
Biological samples
Human colon cancer tissue
Specimens of human colon were obtained from a previ-
ous study, where total RNA was extracted to evaluate
microRNA expression profiles [7]. Briefly, specimens
from patients with CC or polyps were snap frozen in li-
quid nitrogen at the time of collection and then stored
at −80°C for later use. Normal areas of colonic epithe-
lium were obtained from either the margin of resection
or adjacent to the tumor. Rectal cancers were excluded.
Polyps were evaluated for histologic type, with only
tubulovillous adenomas selected for study. Pathologic
tumor staging was classified according to Dukes’ criteria
[8]. DNA mismatch repair (MMR) status was evaluated
as previously described [7]. Further, all samples included
in the present study were anonymized, and comprised
284 colon samples, including 53 normal colon, 39
adenomas, 51 dMMR carcinomas, and 141 pMMR
carcinomas.
The Mayo Clinic Institutional Review Board reviewed
and approved for human studies the protocol entitled
“The Identification and Validation of miRNA Signature
Profiles as Biomarkers for Colon Cancer Progression”
from Dr. Stephen N. Thibodeau. The Committee noted
that the human studies aspects involve the use of sam-
ples collected under IRB-approved protocols. The Com-
mittee determined that the consenting process allows for
future use of the samples as exemplified in the current
protocol. The majority of patients provided written in-
formed consent. For those who did not, samples were
anonymized.
Mouse brain tissue
Specimens of mouse brain were also made available
from a previous study, where total RNA was extracted
to evaluate microRNA expression profiles [9]. Eight-
month old male APP/PS1 double-transgenic mice [10]
and their wild-type littermates were used in this study,
comprising 5 cortex and 5 hippocampus samples from
WT and APP/PS1 animals. Animals were sacrificed by
cervical dislocation and the brains removed. All proto-
cols have been reviewed and approved by the animal
ethics committee of the University of Leuven. Onehemisphere was dissected into hippocampus and frontal
cortex, and snap-frozen for subsequent RNA and protein
extraction.Human colon cancer cells
HCT116 human colorectal carcinoma cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen Corp.) supplemented with 10% fetal bo-
vine serum and 1% antibiotic/antimycotic solution
(Invitrogen Corp.) and maintained at 37°C in a humidi-
fied atmosphere of 5% CO2, as previously described
[11,12].Sample processing and protein extraction
Human colon cancer tissue
Frozen tissue sizes equivalent to 7 mm2 and 10-μm thick
were sectioned and placed in a vial containing 400 μl of
RLT buffer (QIAGEN, Chatsworth, CA) including 4 μL
of β-mercaptoethanol. The vials were stored at −80°C
until utilized for RNA extraction using TRIzolWLS
(Invitrogen Corp.) according to the manufacturer’s in-
structions [7]. Following RNA extraction, after the
addition of chloroform and phase separation with re-
moval of the aqueous phase containing the RNA, the
interphase and the organic phase of the TRIzolW-
chloroforms were stored at −80°C for 2 years, until
processed for protein extraction.Mouse brain tissue
Frozen hippocampus and frontal cortex tissues were
stored at −80°C until utilized for RNA extraction using
TRIzolW (Invitrogen Corp.) according to the manufac-
turer’s instructions. Following RNA extraction for use in
a study to evaluate AD-related gene expression [9], the
interphase and the organic phase of the TRIzolW-
chloroform extracts were stored at −80°C for 3 months,
until processed for protein extraction.Total protein isolation
To compare protein extraction methods, HCT116 cells
were plated in 100 mm plates at 106 cells per plate.
Forty-eight hours later, each plate was individually
scraped, and cells collected together with cell culture su-
pernatants, to standardize inputs for protein extraction.
Next, cell suspensions were centrifuged at 500 g, 5 min
at 4°C, and the supernatants were discarded. Cell pellets
were resuspended in the respective protein extraction re-
agent for each method, including Cell Disruption Buffer
using the commercial mirVana™ PARIS™ kit (#AM1556;
Invitrogen Corp.); A+2X Buffer using a standardized la-
boratory protocol [11-13]; or TRIzolW using the TRIzolW
manufacturer’s protocol with and without modifications.
Figure 1 Modified TRIzol protein extraction. The protocol
followed for protein extraction from the TRIzolW-chloroform fractions is
depicted as a flow chart. The extracted proteins were stored at −80°C
until further analysis. *According to TRIzolW manufacturer’s instructions.
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Ice-cold cell disruption buffer was added to cell pellets,
followed by vigorous vortexing to improve cell lysis.
Samples were then incubated on ice for 10 min. Subse-
quently, samples were sonicated, and cleared by centrifu-
gation at 3,200 g or 10,000 g for 10 min, at 4°C. The
clear supernatants containing the total protein extracts
were transferred to a fresh tube and stored at -80°C.
A+2X buffer
Ice cold 1:1 solution of buffer A (10 mM Tris–HCl, pH
7.6, 5 mM MgCl2, 1.5 mM KAc, 2 mM dithiothreitol
(DTT) and Halt™ Protease and Phosphatase inhibitor
cocktail, EDTA-free (#78445, Thermo Scientific)) and buf-
fer 2X (10 mM Tris–HCl pH 7.6, 1% Nonidet-P40 and
Halt™ Protease and Phosphatase inhibitor cocktail) was
added to cell pellets, and the samples were homogeneized
by vigorous vortexing and incubated on ice for 30 min.
Next, samples were sonicated, centrifuged at 3,200 g or
10,000 g for 10 min, at 4°C. The clear supernatants
containing the total protein extracts were transferred to a
fresh tube and stored at −80°C.
TRIzolW
Total protein extracts were obtained following the man-
ufacturer’s instructions, until the protein solubilisation
step. In parallel, protein pellets were solubilized in: 1%
SDS, with and without 1 h incubation in a 50°C water
bath; 1:1 solution of 1% SDS and 8 M urea, with and
without 1 h of sample incubation in a 50°C water bath;
and 1:1 solution of 1% SDS and 8 M urea, with sonic-
ation (modified TRIzol protocol). Samples were clarified
by centrifuging at 3,200 g or 10,000 g to sediment insol-
uble material. The clear supernatants containing the
total protein extracts were transferred to fresh tubes and
stored at −80°C.
Modified TRIzol protocol
The flow chart in Figure 1 depicts the protocol followed.
This protein extraction protocol was common to all sam-
ples from human colon and colon cancer cells, mouse
brain, and mouse primary cortical neurons, adjusting the
volumes of reagents to TRIzolWLS or TRIzolW processed
samples, according to the manufacturer’s instructions.
Briefly, the tube containing the organic phase and a small
portion of aqueous phase (TRIzolW-chloroform fractions)
from previous phase separation was centrifuged at 12,000
g for 15 min at 4°C, and the remaining aqueous phase
supernatant was removed and discarded. Subsequently,
100% ethanol was added to precipitate DNA. Tubes were
mixed by inversion and centrifuged at 2,000 g for 5 min,
at 4°C. The phenol-ethanol supernatant was removed to 2
mL tubes, for protein extraction. Protein was precipitated
with isopropanol, followed by mixing, and 10 minincubation at room temperature. Subsequently, samples
were centrifuged at 12,000 g for 10 min and the super-
natant discarded. Protein pellets were next washed three
times with 0.3 M guanidine hydrochloride in 95% ethanol.
In each wash, tubes were vigorously shaken, incubated at
room temperature for 20 min followed by centrifugation
at 7,500 g for 5 min at 4°C. After the final wash and spin,
100% ethanol was added, and samples incubated at room
temperature for 20 min, followed by a final centrifugation
at 7,500 g for 5 min at 4°C. The supernatant was removed
and a 1:1 solution of 1% SDS and 8 M urea in Tris–HCl 1
M, pH 8.0 was added to the protein pellets, followed by 5
cycles of 15 sec sonication and 30 sec ice incubation, to
solubilize the protein, a modification from the 1% SDS re-
suspension solution recommended in the manufacturer’s
protocol. Sonication was performed using a compact
ultrasonic device with amplitude adjusted to 80% and
pulse to 90% (model UP100H, Hielscher Ultrasonics
GmbH, Teltow, Germany - 100 watts, ultrasonic fre-
quency 30 kHz). Next, the samples were centrifuged at
3,200 g for 10 min at 4°C, to sediment insoluble material.
The supernatant containing the solubilized proteins was
transferred to a fresh tube and stored at −80°C.
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Protein concentration was determined using the Brad-
ford method with the Bio-Rad Protein Assay kit (Bio-
Rad, California, USA), according to the manufacturer’s
instructions. This method involves the addition of an
acidic dye, CoomassieW Brilliant Blue G-250, and subse-
quent absorbance measurement at 595 nm. Bovine albu-
min was used as standard (New England Biolabs Inc.,
New England). Absorbance was measured in a UNICAM
UV/Vis 2 spectrophotometer (Speck & Burke Analytical,
Clackmannanshire, Scotland) at 595 nm. The protein
concentrations were determined from interpolation of
absorbance on a linear regression standard curve.Immunobloting
Human colon cancer tissue and human colon cancer cells
Steady-state protein expression levels were determined by
immunoblot analysis. Briefly, 40 μg of total protein ex-
tracts were separated on 8% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). After
electrophoretic transfer onto nitrocellulose membranes,
immunoblots were blocked with 5% milk solution for
30 min. Subsequently, blots were incubated overnight at
4°C with primary rabbit anti p-Akt, Akt, NF-κB (p65),
IκB-α, and PARP (#sc-7985-R, #sc-8312, #sc-372, #sc-371,
#sc-7150, respectively) and with primary mouse anti
GAPDH, p53 (#sc-32233 and #sc-126, respectively ), all
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA,
USA), and β-actin (#A-5441; Sigma-Aldrich). Next, immu-
noblots were incubated with anti-rabbit or anti-mouse se-
condary antibody conjugated with horseradish peroxidase
(Bio-Rad Laboratories) for 3 h at room temperature. Finally,
blots were processed for protein detection using Super
Signal™ substrate (Pierce, Rockford, IL, USA). Ponceau S
dye at 0.2% (w/v) (Merck KGaA, Darmstadt, Germany)
staining of immunoblots was used as a loading control.
Mouse brain tissue
Sixty μg of total protein extracts from dissected hippo-
campus and frontal cortex were separated on 6 and 12%
SDS-PAGE. Electrophoretic transfer and immunoreacted
protein bands were visualized as described above for hu-
man colon samples. The primary antibodies included
rabbit polyclonal antibodies reactive to ApoE and SORLA
(#sc-98574 and #sc-33822, respectively; Santa Cruz Bio-
technology), and mouse monoclonal antibody reactive to
β-Actin (Sigma-Aldrich). β-Actin or Ponceau S dye stain-
ing was used as loading controls. In addition, 60 μg of
total protein extracts from hippocampus were electro-
phoretically resolved on 10-20% Tris-Tricine gels (BioRad
Laboratories), and human APP, APP-C-terminal fragment
β (APP-CTF-β) and amyloid-β (Aβ) peptide were identi-
fied using a primary mouse monoclonal antibody reactiveto human Aβ (6E10; Signet, Emeryville, CA). Ponceau S
dye staining was used as loading control.
Sandwich ELISA
Total protein extracts from dissected hippocampus and
frontal cortex from APP/PS1 mice were also used to de-
termine Aβ1–42 to Aβ1–40 ratios. Human total Aβ1–40 or
Aβ1–42 content was measured by sandwich ELISA
(#EZBRAIN40 and #EZBRAIN42, respectively; Millipore
Corporation, Billerica, MA, USA) according to the man-
ufacturer’s instructions, with minor modifications in the
sample preparation step. Briefly, 10 ng of total protein
extracts were adjusted to a final volume of 50 μL with
the reagent Standard and Sample Diluent, supplied by
the kit. All subsequent assay procedure was carried out
following the manufacturer’s instructions.
Densitometry and statistical analysis
The relative intensities of protein bands were analyzed
using the densitometric analysis program Quantity One
version 4.6 (Bio-Rad Laboratories). All data are
expressed as the mean ± SEM of similar samples, from
three independent experiments. Protein band intensities
for each human colon cancer sample, in all blots, were
normalized to the mean protein band intensities from
duplicate HCT116 total protein sample present in the
same blot, and similarly included in all blots. HCT116
protein extracts used as internal normalization controls
in each blot were all from the same batch. Statistical sig-
nificance was evaluated using the non-parametric statis-
tical analysis Kruskal-Wallis test with Dunn’s post-test
for selected comparisons. Values of p < 0.05 were con-
sidered statistically significant.
Results and discussion
Performance of modified TRIzol protocol
In the present study, we tested two simple modifications
to the TRIzolW and TRIzolWLS manufacturer’s protocol,
which resulted in a fast, and almost complete,
solubilization of the protein pellet. The modified proto-
col involves the use of a 1:1 mixture of 1% SDS and 8 M
urea as protein solubilization solution, and requires son-
ication. Different protein extraction protocols make use
of different centrifugation speeds to clarify protein sam-
ples by sedimenting insoluble materials, in the final step
of the extraction protocol. We showed that no signifi-
cant differences in protein patterns were detected be-
tween protein samples recovered following 3,200 g or
10,000 g centrifugation, as revealed by Ponceau and
Coomassie stainings (Figure 2). To evaluate protein re-
covery, we compared the total amount of protein
obtained with modified TRIzol protocol, with that
obtained using commercial (mirVana™ PARIS™), stan-
dardized laboratory (A+2X buffers), and TRIzolW total
Simões et al. BMC Genomics 2013, 14:181 Page 6 of 14
http://www.biomedcentral.com/1471-2164/14/181protein extraction methods. The results highlight the
relevance of the sonication step, where the amount of
protein recovered from the modified TRIzol protocol is
much higher compared to the same protocol without
sample sonication (Figure 3, lanes 5 and 6, versus lanes
7 to 10), and to the TRIzolW and TRIzolWLS manufac-
turer’s protocols, which resulted in undetectable, or very
low protein recovery, even after 1 h incubation at 50°C
(Figure 3, lanes 5 and 6, versus lanes 11 to 14). However,
in comparison with the commercial mirVanaTM
PARISTM and standardized extraction protocols, our
protocol allows the recovery of ~ 50% of total protein
collected by these methods (Figure 3, lanes 5 and 6, ver-
sus lanes 1 to 4). Collectively, these results show that
our modification to the TrizolW manufacturer’s protocol
greatly improved protein recovery from TRIzolWFigure 2 Performance of the modified TRIzol protocol evaluated by P
the modified TRIzol protocol versus the TRIzolW manufacturer’s, mirVanaTM PAR
cells were plated in 14 independent 100 mm plates (one per experimental sett
48 h after plating. Next, 40 μg of total protein extracts were separated on 8% S
staining of the nitrocellulose membrane following electrophoretic transfer of p
SDS-PAGE gel separation.processed samples, where the sample sonication step
seemed to play an important role.
In a transcriptomic and proteomic analysis performed
using small samples of rat spinal cord, it was shown that
although providing similar RNA recovery yield, the pro-
tein recovery yield can be increased by processing sam-
ples using AFD followed by protein extraction using
TRIzolW, as compared to direct sample homogenization
in TRIzolW [4]. Further, protein recovery yield using
AFD followed by extraction of proteins with TRIzolW
was ~ 5% lower than protein extraction using AFD
followed by CHAPS/urea protein extraction [4]. How-
ever, direct sample homogeneization in TRIzolW also
provided a much lower protein recovery yield compared
to both protein extractions using AFD, being ~ 20-25%
lower than AFD followed by CHAPS/urea proteinonceau S and Coomassie staining. To compare the performance of
ISTM kit and standardized laboratory (A+2X Buffers) protocols, 106 HCT116
ing: lanes 1 to 14), and cells were processed for total protein extraction
DS-PAGE and transferred onto nitrocellulose membrane. Ponceau S
roteins, and Coomassie blue staining of total protein extracts following 8%
Figure 3 Performance of the modified TRIzol protocol assessed by total protein extract protein recovery (mg mL-1). To compare the
performance of the modified TRIzol protocol versus the TRIzolW manufacturer’s, mirVanaTM PARISTM kit and standardized laboratory (A+2X Buffers)
protocols, 106 HCT116 cells were plated in 14 independent 100 mm plates (one per experimental setting: lanes 1 to 14), and cells were processed for
total protein extraction 48 h after plating. Protein extracts were processed in 100 μl of extraction buffer (samples 1–4), or resuspended in 100 μl of
buffer (samples 5–14). Modified TRIzol protocol allowed up to ~50% recovery of total protein content in comparison with mirVanaTM PARISTM kit and
standardized laboratory (A+2X Buffers), but importantly allowed a much higher protein recovery compared to the TRIzol manufacturer`s protocol,
whose recovery yield was not suitable for downstream applications.
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ple homogenization in TRIzolW was higher than the
yield we report, although the approaches are not entirely
comparable. Protein extraction from rat spinal cord
samples used in that study was performed from pooled
organic and aqueous fractions, following RNA extraction
and precipitation, whereas in our study proteins were
only extracted from the organic phases of TRIzolW-
Chloform processed samples, following removal of the
aqueous phase. This may account for the differences in
protein yield. Importantly, in the same study, and despite
marked differences in protein recovery yield of sample
homogenates processed directly in TRIzolW or by AFD
followed by TRIzolW, these samples were evaluated by
microarray and 2DE analyses. Furthermore, it was
shown that the two homogenization strategies were ef-
fectively interchangeable from the perspective of the
genomics analysis, and that TRIzolW provided effective
protein recovery, with only minor alterations to the re-
solved proteome. In fact, at the level of 2DE, both sam-
ple processing methods resulted in high quality and
resolution proteomic maps of the biological material
with only 58 proteins found significantly differentbetween both preparations, where 14 proteins were only
detected by using a single sample preparation, and the
remaining 44 proteins were detected in both prepara-
tions but differed significantly in relative abundance,
which may also be attributable to sample to sample dif-
ferences in protein abundance [4].
The protein patterns we obtained from total protein
extract separation in 8% SDS polyacrylamide gel, follow-
ing Ponceau or Coomassie staining, clearly demon-
strated that the modified TRIzol protocol allows a
staining pattern for recovered proteins similar to that
obtained following mirVana™ PARIS™ and standardized
laboratory protein extraction protocols (Figure 2, lanes 5
and 6, versus lanes 1 to 4). Further, the protein patterns
and recovery yield obtained from the modified TRIzol
protocol without sonication, and from the TRIzolW and
TRIzolWLS manufacturer’s protocol were not representa-
tive of the protein content in the samples. In fact, they
displayed different staining patterns from those obtained
with the modified TRIzol protocol, and with the
mirVana™ PARIS™ and standardized laboratory protocols
(Figures 2 and 3, lanes 7–10 and 11–14, respectively,
versus lanes 1–6). However, 1D gels may provide a
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test as to whether or not selective extraction of particu-
lar individual proteins may occur. Nevertheless, using a
similar input of a particular tissue type, putative selective
expression of a given protein would be more likely to
derive from extraction method specificities rather than
derive from sample to sample abundance. Therefore, the
applicability of this method to the evaluation of steady-
state expression of the whole proteome, particularly for
undetectable proteins or to quantitative analysis, needs
further testing.
Importantly, to validate the performance of the modi-
fied TRIzol protocol, we evaluated the steady-state ex-
pression levels of the housekeeping proteins GAPDH
and β-actin. In addition, we also evaluated the steady-
state expression levels of the nuclear protein PARP, and
of other proteins whose expression changes have been
previously reported in cancer, including NF-κB, IκB, p53
and Akt. Our results demonstrated that the steady-state
expression levels of β-actin and GAPDH obtained with
the modified TRIzol protocol are very similar to those
obtained with mirVana™ PARIS™ and standardized la-
boratory protocols (Figure 4, lanes 5 and 6, versus lanes
1–4). However, when total proteins are obtained by the
modified TRIzol protocol without sonication, and by theFigure 4 Performance of the modified TRIzol protocol evaluated by im
TRIzolW manufacturer’s, mirVana™ PARIS™ kit and standardized laboratory (A
independent 100 mm plates (one per experimental setting: lanes 1 to 14),
Next, 40 μg of total protein extracts were separated on 8% SDS-PAGE and
steady-state expression levels of housekeeping proteins (β-actin and GAPDTRIzolW manufacturer’s protocol, we found striking dif-
ferences (Figure 4, lanes 7–14 versus lanes 1–6). Worthy
of note, the abundant cellular protein β-actin was un-
detectable in protein samples obtained with the TRIzolW
manufacturer’s protocol, and almost undetectable in
protein samples that were not sonicated (Figure 4, lanes
11–14, and lanes 7–10, respectively), thus highlighting
the poor, and unreliable, protein recovery performance
of these methods, in comparison with the modified
TRIzol protocol.
It is known that multiple proteins involved in the regula-
tion of key cellular functions are deregulated in many dis-
eases, including cancer. To further test the performance of
the modified protein extraction protocol, we evaluated the
steady-state levels of NF-κB, IκB, p53, p-Akt and Akt. Our
results clearly showed that we were able to detect these
proteins, with comparable sensitivity to that obtained using
mirVana™ PARIS™ and standardized laboratory protocols
(Figure 4, lanes 5 and 6 versus lanes 1–4); and improved
sensitivity compared to the TRIzolW manufacturer`s proto-
col and to the modified TRIzol protocol without sonication
(Figure 4, lanes 5 and 6 versus lanes 11–14 and 7–10, re-
spectively). Furthermore, it is also possible to detect phos-
phorylated proteins, such as p-Akt, illustrating the ability to
detect these post-translational protein modifications inmunoblotting. To compare the modified TRIzol protocol versus the
+2X Buffers) protocols, 106 HCT116 cells were plated in 14
and cells were processed for total protein extraction 48 h after plating.
transferred onto nitrocellulose membrane. Immunoblot analysis of
H), NF-κB, IκB, p-Akt, Akt, p53, and nuclear PARP.
Figure 5 Ponceau S staining is comparable to β-actin as a
loading control for immunobloting. HCT116 cells were plated at
106 per 100 mm plate, and cells were processed for protein
extraction with standardized laboratory A+2X protocol, 48 h after
plating. Increasing input of protein extract, from 20 to 140 μg with
20 μg increments, were next separated in 8% SDS-PAGE followed by
transfer to nitrocellulose membrane, Ponceau S staining and β-actin
steady-state expression evaluation. (A) Representative Ponceau S
staining and steady-state expression levels of β-actin. (B) Correlation
between Ponceau S and β-actin relative quantification, from three
independent experiments.
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http://www.biomedcentral.com/1471-2164/14/181TRIzolW treated samples using the modified TRIzol proto-
col. Finally, the modified TRIzol protocol is suitable to de-
tect nuclear PARP (Figure 4, lanes 5 and 6). PARP is
undetected from total protein extracts processed by the
TRIzolW manufacturer’s protocol, and is hardly detectable
by using modified TRIzol protocol without sonication
(Figure 4, lanes 11–14 and 7–10, respectively). Worthy of
note, PARP is a 116 kDa nuclear protein, cleaved by
caspase-3 upon apoptotic stimuli, yielding an 85 kDa frag-
ment. With the modified TRIzol protocol, it was possible to
detect the full length and the cleaved fragment, with in-
creased sensitivity compared to other protocols.
Ponceau S staining as immunobloting loading control
We and others have used Ponceau S staining as a load-
ing control for western blot [14-16]. This is particularly
relevant when experiments require protein separation in
low percentage SDS polyacrylamide gels, in which the
typical housekeeping controls migrate out of the gel. In
addition, it is also important in conditions in which the
typical housekeeping proteins are not adequate controls,
due to changes in their steady-state expression levels, in-
cluding during stem cell differentiation [14,16]. In this
study, we validated the performance and used Ponceau
staining as a normalization control for immunoblot ana-
lysis. For this purpose, we separated total protein ex-
tracts in 8% SDS polyacrylamide gel, using 20 to 140 μg
of total protein extracts as input, and evaluated the
steady-state expression of the housekeeping loading con-
trol, β-actin (Figure 5A). We next quantitated Ponceau
and β-actin signals, and showed a strong correlation be-
tween both signals, for the range of protein inputs tested
(20 to 140 μg, with 20 μg increments; R = 0.97 ± 0.007)
(Figure 5B). We also evaluated the ratio of β-actin over
Ponceau (β-actin/ponceau), for several immunoblots
with 5–10 samples each, and performed linear regression
analysis. The equation slopes provided a measure of
variability between β-actin and Ponceau staining as
normalization controls. The closer the slope is to zero,
the higher is the concordance between both variables.
Our results provided a mean slope of 0.0003 ± 0.0003
(data not shown), highlighting that sample normalization
with Ponceau staining is equally effective as the regular
sample normalization with the housekeeping β-actin.
Steady-state protein expression levels in human colon cancer
In this study, using the modified TRIzol protocol and
Ponceau as normalization control, we evaluated the
steady-state protein expression of p53, NF-κB and its in-
hibitor IκB, and p-Akt and Akt, in a large set of well-
defined human colon samples, including normal colonic
mucosa, tubolovillous adenomas, pMMR and sporadic
dMMR adenocarcinomas. These samples were previously
processed with TrizolWLS for RNA extraction, which wasused for the evaluation of miRNA expression profiles [7].
The TRIzolW-chloroform fractions of these human colon
samples were stored at −80°C for 2 years, before they were
processed for total protein extraction following our modi-
fied TRIzol protocol. We next used these protein extracts
to evaluate if following 8% SDS polyacrylamide gel separ-
ation, immunoblot detection of these proteins reproduced
their reported steady-state expression levels in CC. Fol-
lowing the modified TRIzol protocol, these proteins were
Simões et al. BMC Genomics 2013, 14:181 Page 10 of 14
http://www.biomedcentral.com/1471-2164/14/181easily detectable (Figure 6A), allowing the evaluation of
the steady-state levels of p53, NF-κB and its inhibitor IκB,
and p-Akt and Akt.
Loss of p53 function by mutation is a common event in
cancer, at rates varying between 10% and close to 100%.Figure 6 Steady-state protein expression levels in human colon cance
samples stored in TRIzolW-chloroform samples at −80°C for 2 years. Forty μ
to nitrocellulose membrane and evaluated for the steady-state protein exp
levels of p53, NF-κB, IκB, p-Akt and Akt, in HCT116 colon carcinoma cells, n
carcinomas. (B) p53 protein steady-state levels in normal colon, colon aden
NF-κB/IκB ratio; and (D) p-Akt, Akt, and p-Akt/Akt ratio. Results are expresse
normal colon; §p < 0.01 and ‡p < 0.05 from colon adenomas; #p < 0.01 froThese mutational events have been reported to occur at
different phases of the multistep process of malignant
transformation [17]. However, the loss of p53 function in
CC is usually associated with adenoma to carcinoma tran-
sition [18,19]. In most cases, the p53 gene mutation givesr samples. Protein extracts were obtained from human colon cancer
g of total protein extracts were separated in 8% SDS-PAGE, transferred
ression levels. (A) Representative imunoblots of steady-state expression
ormal colon, colon adenomas and colon pMMR and dMMR
omas, and pMMR and dMMR colon carcinomas; (C) NF-κB, IκB, and
d as mean ± SEM for similar samples. *p < 0.01 and †p < 0.05 from
m colon sporadic dMMR carcinomas.
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http://www.biomedcentral.com/1471-2164/14/181rise to a stable mutant protein, which tends to accumulate
in the cell [17]. Loss of heterozygosity is believed to be the
main inactivation event on one of the alleles of tumor sup-
pressor genes in cancer, where approximately 70% of CC
displays 17p LOH. In most cases of CC, the main target of
17p LOH is the p53 gene; and ~ 85% of the somatic muta-
tions carried in the remaining p53 allele are missense mu-
tations [20]. In addition, the loss of functional p53 in
adenomas and dMMR carcinomas represents the minority
of cases, in contrast to pMMR carcinomas, where p53 is
frequently mutated [19,21]. The lower rate of p53 muta-
tion might also be related with the better prognosis associ-
ated with CC presenting MSI (dMMR) in contrast to CC
exhibiting an intact mismatch repair system (pMMR) [22].
In addition, p53 is critically involved in drug-induced
apoptosis, in which it is up-regulated and translocated to
mitochondria following HCT116 colon cancer cells expos-
ure to 5-fluorouracil [23].
Our results showed increased p53 steady-state levels
in adenomas as well as in pMMR and dMMR tumors
(p < 0.01) (Figure 6B). Importantly, p53 levels in aden-
omas and dMMR carcinomas were much lower than
those found in pMMR carcinomas, which might be asso-
ciated with an attempt to control cell growth, rather
than reflect p53 mutations. The high steady-state levels
of p53 found in pMMR carcinomas were possibly related
to the accumulation of stable mutant forms of p53. The
present results are in accordance with the literature, and
suggest that the loss of functional p53 is indeed involved
in the adenoma to carcinoma transition, and that the
status of the mismatch repair system is strongly corre-
lated with the frequency of p53 mutations [24].
The NF-κB and PI3K/Akt signaling pathways are fre-
quently deregulated in several types of cancer, including
CC [13]. Abnormal NF-κB and Akt activation and
overexpression was shown to play an important role in
cellular transformation, and may lead to uncontrolled
cell growth and survival, apoptosis suppression, and
increased angiogenesis and metastasis [25-27]. The
overexpression and activation of NF-κB in CC have been
particularly associated with colon tumor progression
[28,29]. In turn, Akt overactivation is typically more
common then its overexpression, due mainly to the
overexpression of EGFR in this type of cancer [27]. In
addition, the involvement of Akt in sporadic colon car-
cinogenesis has already been reported as an important
early event [30]. For the evaluation of the NF-κB and
Akt signaling pathways we analysed NF-κB and IκB, and
p-Akt and Akt steady-state levels, respectively. To assess
NF-κB and Akt activation we calculated the ratio of NF-κB
over IκB, and p-Akt over Akt, respectively, in normal co-
lonic mucosa, colon adenomas, and colon pMMR and
dMMR carcinomas. The results clearly show that NF-κB
is overexpressed in colon adenomas, pMMR carcinomas,and also dMMR carcinomas, compared to normal colon
tissue (p < 0.01) (Figure 6C, left panel). Further, our data
also indicated that NF-κB is aberrantly overactivated in
colon adenomas (p < 0.05) and in pMMR and dMMR tu-
mors (p < 0.01), compared to normal colonic tissue
(Figure 6C, right panel). In turn, our results showed that
p-Akt steady-state levels were significantly increased in ad-
enomas (p < 0.01) and displayed a trend for increase in
both pMMR and dMMR carcinomas compared to normal
colon tissue (Figure 6D, left panel). Akt levels displayed a
trend for increase in adenomas and pMMR carcinomas,
and were found significantly elevated in dMMR carci-
nomas (p < 0.01), compared to normal colon tissue
(Figure 6C, middle panel). Importantly, Akt activation was
significantly increased in adenomas compared to normal
tissue and to pMMR and dMMR carcinomas (p< 0.01)
(Figure 6D, right panel). Therefore, our results indicated
aberrant NF-κB signaling in colon adenomas and carcin-
omas, and suggested that overactivation of Akt signaling
may represent an early event in CC. Collectively, these
studies showed that our modified TRIzol protein extrac-
tion protocol is an adequate technique to evaluate the
steady-state levels of proteins in human cancer, represen-
ting a fast, cost-effective alternative to allow adequate
protein extraction from samples that were simultan-
eously processed for nucleic acid extraction and follow-
ing prolonged storage, which significantly expands the
current known applicability of TRIzolW protein ex-
tracts. Further, our report significantly highlights the
relevance, and ease of access, of potentially relevant in-
formation obtainable from protein expression analyses
by immunoblot, following protein extraction from or-
ganic fractions of routine TRIzolW processed samples,
which are usually discarded. In studies in which tissue
samples have already been collected and TRIzolW- or
TRIzolWLS-processed, our method provides a simple,
fast and cost-effective way of accessing relative protein
expression by immunoblot.
Steady-state protein expression levels in mouse brain
In AD, Aβ peptides are generated by successive proteolysis
of APP that is initially cleaved by β-secretase, and subse-
quently by γ-secretase [31-33]. In this study, we evaluated
APP and APP-C-terminal fragment cleaved by β-secretase
(CTF-β) steady-state protein levels, using proteins col-
lected from brain tissues of APP/PS1 mice and wild-
type littermates, with the modified TRIzol protocol and
Ponceau as normalization control. For protein isolation,
we used the TRIzolW-chloroform extracts stored at −80°C
for 3 months following RNA extraction [9]. We next
performed electrophoresis in 10-20% Tris-Tricine gels,
followed by immunodetection of human APP full-length,
APP-CTF-β, and Aβ. As expected, APP and its fragments
were only detected in APP/PS1 mice (Figure 7A).
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presence of the ε4 allele of the apolipoprotein E (ApoE)
gene [34], which encodes a protein that contributes to AD
pathogenesis by modulating the metabolism and aggrega-
tion of Aβ peptide and by directly regulating brain lipid
metabolism and synaptic function through apoE receptors
(reviewed in [35]). Indeed, ApoE itself binds Aβ with high
specificity and is present in AD senile plaques [36]. In
contrast, sortilin-related receptor with A-type repeats
(SORLA), an ApoE-binding protein, may play a protective
role in AD by reducing APP processing and generation of
Aβ peptides [37]. Accordingly, loss of SORLA occurs in
AD brain patients [38]. Therefore, given the role of lipid
mediators in modulating Aβ metabolism [39], we assessed
ApoE and SORLA protein steady-state levels. Western
blot analysis of total protein extracts demonstrated in-
creased steady-state expression of ApoE in the hippocam-
pus and frontal cortex of APP/PS1 mice compared to
control wild-type mice, whereas decreased expression of
SORLA was observed in both cerebral regions of APP/Figure 7 Steady-state protein expression levels in mouse brain samp
brain samples stored in TRIzolW-chloroform samples at −80°C for 3 months
mice hippocampus were electrophoretically separated in 10-20% Tris-Tricin
steady-state protein expression levels of human APP, APP-C-terminal fragm
used as loading control. (B) Sixty μg of total protein extracts from WT and
and 12% SDS-PAGE, transferred to nitrocellulose membrane and evaluated
β-Actin and/or Ponceau S staining were used as loading controls. (C) Ten n
frontal cortex (H and FC, respectively) were used to measure human total A
individual Aβ1–42 to Aβ1–40 ratio. Data are mean ± SEM from 5 mice in eacPS1 mice (Figure 7B). Finally, we analyzed human Aβ1-42
and Aβ1-40 levels in the hippocampus and frontal cortex
of APP/PS1 mice brains by sandwich ELISA (Figure 7C).
Aβ1-42 to Aβ1-40 ratio is an important factor in determin-
ing the fibrillogenesis, toxicity, and pathological distribu-
tion of Aβ, and appears to correlate with AD pathology
[40]. In APP/PS1 mice hemibrains, Aβ1-42 to Aβ1-40 ratio
was shown to increase with AD progression from 1.6 to 5
in 1- and 8-month-old mice, respectively [10]. Our results
on dissected hippocampus and frontal cortex are in agree-
ment with the high value expected for Aβ1-42 to Aβ1-40 ra-
tio. Therefore, the modified TRIzol protocol for protein
extraction provides an adequate tool for protein analysis
in brain tissue samples, coupled to RNA analysis. This
was particularly apparent for the specific detection of
intracellular Aβ accumulation and APP processing, the
detection of variations in key proteins associated with AD
pathogenesis between wild-type and transgenic mice sam-
ples, and the measurement of Aβ1-42 and Aβ1-40 levels by
ELISA. Similar sensitivity of the modified TRIzol protocolles. Protein extracts were obtained from APP/PS1 and wild-type mice
. (A) Sixty μg of total protein extracts from wild-type (WT) and APP/PS1
e gels, transferred to nitrocellulose membrane and evaluated for the
ent β (CTF-β) and amyloid-β (Aβ) peptide. Ponceau S staining was
APP/PS1 mice hippocampus and frontal cortex were separated in 6
for the steady-state protein expression levels of apoE and SORLA.
g of total protein extracts from APP/PS1 mice hippocampus and
β1–40 or Aβ1–42 content by sandwich ELISA, and to determine
h brain region.
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neurons incubated with Aβ (data not shown).
Conclusions
Our results clearly demonstrated that simple modifica-
tions introduced to the TRIzolW manufacturer’s protocol,
consisting of protein resuspension using 1:1 solution of
1% SDS and 8 M urea followed by sonication, greatly
improved the protein recovery performance. This mo-
dified protocol allows higher protein recovery yield,
while producing protein patterns comparable to those
obtained by other extraction methods, following SDS-
PAGE and Coomassie or Ponceau staining. In addition,
we demonstrated the importance of the sample sonic-
ation step for efficient ressuspension of the recovered
protein pellet. Our modified TRIzol protocol also al-
lowed the detection of post-translational modifications,
namely protein phosphorylation, and cellular protein
distribution. In addition, our results further validated the
use of Ponceau as a loading control, demonstrating that
Ponceau S staining and β-actin relative quantification
provided comparable performance, which is particularly
relevant when regular housekeeping proteins are inad-
equate controls, e.g., during stem cell differentiation.
Furthermore, our modified method allowed the detec-
tion and relative quantification of steady-state expression
levels of important proteins deregulated in disease con-
ditions, reproducing the current literature. However, we
cannot conclude if our method would be suitable for
quantitative protein analysis, nor for mass spectrometry
since high concentrations of urea may lead to protein
carbamylation. Collectively, we present a simple, fast,
and inexpensive modified TRIzol protocol for protein
extraction, which allows the recovery of total protein ex-
tracts from multiple sources, and its applicability to
good quality immunoblot detection of the steady state
protein expression levels from samples that have simul-
taneously been processed for nucleic acid extraction, fol-
lowing prolonged storage in TRIzolW-chloroform at −80°.
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